protein

p70S6K, Unactive recombinant protein

MBS515409

0.02 mg

270 USD

Recombinant Protein

p70S6K, Unactive recombinant protein

[p70S6K]

[S6K; PS6K; S6K1; STK14A; RPS6KB1; p70-alpha; p70(S6K)-alpha]

[Homo sapiens ribosomal protein S6 kinase, 70kDa, polypeptide 1 (RPS6KB1), transcript variant 1, mRNA; Ribosomal protein S6 kinase beta-1; ribosomal protein S6 kinase beta-1; p70 S6 kinase, alpha; ribosomal protein S6 kinase I; serine/threonine kinase 14 alpha; serine/threonine-protein kinase 14A; ribosomal protein S6 kinase, 70kDa, polypeptide 1; 70 kDa ribosomal protein S6 kinase 1; P70S6K1; p70-S6K 1; Ribosomal protein S6 kinase I; Serine/threonine-protein kinase 14A; p70 ribosomal S6 kinase alpha]

[p70S6K]

[S6K; PS6K; S6K1; STK14A; RPS6KB1; p70-alpha; p70(S6K)-alpha]

[RPS6KB1; RPS6KB1; S6K; PS6K; S6K1; STK14A; p70-S6K; p70 S6KA; p70-alpha; S6K-beta-1; p70(S6K)-alpha; STK14A; S6K-beta-1; S6K1; P70S6K1; p70-S6K 1; p70 S6 kinase alpha; p70 S6K-alpha; p70 S6KA]

KS6B1_HUMAN

Sf9 insect cells

5368

>90%

50mM sodium phosphate, pH 7.0, 300mM NaCl, 150mM imidazole, 0.1mM PMSF, 0.25mM DTT, 25% glycerol.

0.1 ug/ml

Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.Stability: 1 yr at -70 degree C from date of shipment. Shipping : Ships with dry ice

Western Blot (WB)

SDS-PAGE

Type: Recombinant Fusion Protein. Species: Human. Tag Information: GST tag. Expression System: Sf9 insect cells using baculovirus.

Unactive Kinase; Signaling Proteins - Unactive Kinases

Recombinant full-length human p70S6K was expressed by baculovirus in Sf9 insect cells using an N-terminal His tag. Scientific Background: p70S6K is responsible for the phosphorylation of 40S ribosomal protein S6 and is ubiquitously expressed in human adult tissues (1). p70S6K is activated by serum stimulation and this activation is inhibited by wortmannin and rapamycin. p70S6k activity undergoes changes in the cell cycle and increases 20-fold in G1 cells released from G0 (2). p70S6K activation requires sequential phosphorylations at proline-directed residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389 a site phosphorylated by phosphoinositide-dependent kinase 1 (PDK-1).

1. Ferrari, S. et al: S6 phosphorylation and the p70s6k/p85s6k. Crit Rev Biochem Mol Biol. 1994;29(6):385-413. Review. 2. Edelmann, HM. Et al: Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts. J Biol Chem. 1996 Jan 12;271(2):963-71.

440546393

NP_003152.1

NM_003161

P23443

~76 kDa

AMPK Signaling Pathway (198868); Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Angiopoietin Receptor Tie2-mediated Signaling Pathway (137917); B Cell Receptor Signaling Pathway (198909); BDNF Signaling Pathway (712093); CDC42 Signaling Events Pathway (137994); Cytoplasmic Ribosomal Proteins Pathway (198853); ErbB Signaling Pathway (198844); ErbB Signaling Pathway (83049)

This gene encodes a member of the ribosomal S6 kinase family of serine/threonine kinases. The encoded protein responds to mTOR (mammalian target of rapamycin) signaling to promote protein synthesis, cell growth, and cell proliferation. Activity of this gene has been associated with human cancer. Alternatively spliced transcript variants have been observed. The use of alternative translation start sites results in isoforms with longer or shorter N-termini which may differ in their subcellular localizations. There are two pseudogenes for this gene on chromosome 17. [provided by RefSeq, Jan 2013]

Function: Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression. Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the preinitiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at 'Thr-412', which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin. Ref.4 Ref.6 Ref.7 Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.14 Ref.16 Ref.18 Ref.20 Ref.23 Ref.24. Catalytic activity: ATP + a protein = ADP + a phosphoprotein. Enzyme regulation: Activation requires multiple phosphorylation events on serine/threonine residues. Activation appears to be first mediated by phosphorylation of multiple sites in the autoinhibitory domain, which facilitates phosphorylation at Thr-412, disrupting the autoinhibitory mechanism and allowing phosphorylation of Thr-252 by PDPK1. The active conformation of the kinase is believed to be stabilized by a mechanism involving three conserved phosphorylation sites located in the kinase domain activation loop (Thr-252) and in the AGC-kinase C-terminal domain (Ser-394 in the middle of the tail/linker region and Thr-412 within a hydrophobic motif at its end). Activated by mTORC1; isoform Alpha I and isoform Alpha II are sensitive to rapamycin, which inhibits activating phosphorylation at Thr-412. Activated by PDPK1. Ref.3 Ref.13 Ref.19. Subunit structure: Interacts with PPP1R9A/neurabin-1 . By similarity. Interacts with RPTOR. Interacts with IRS1. Interacts with EIF3B and EIF3C. Interacts with POLDIP3 and TRAF4. Ref.5 Ref.6 Ref.7 Ref.10 Ref.16. Subcellular location: Cell junction synapse synaptosome . By similarity. Mitochondrion outer membrane. Mitochondrion. Note: Colocalizes with URI1 at mitochondrion. Ref.14 Ref.18Isoform Alpha I: Nucleus. Cytoplasm Ref.14 Ref.18. Isoform Alpha II: Cytoplasm Ref.14 Ref.18. Tissue specificity: Widely expressed. Ref.2. Domain: The autoinhibitory domain is believed to block phosphorylation within the AGC-kinase C-terminal domain and the activation loop.The TOS (TOR signaling) motif is essential for activation by mTORC1 . By similarity. Post-translational modification: Phosphorylation at Thr-412 is regulated by mTORC1. The phosphorylation at this site is maintained by an agonist-dependent autophosphorylation mechanism . By similarity. Activated by phosphorylation at Thr-252 by PDPK1. Dephosphorylation by PPP1CC at Thr-412 in mitochondrion. Sequence similarities: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily.Contains 1 AGC-kinase C-terminal domain.Contains 1 protein kinase domain.

0.02 mg

270 USD

0.05 mg

450